Trial Profile
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Mirogabalin (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Registrational; Therapeutic Use
- Acronyms REDUCER
- Sponsors Daiichi Sankyo Company
- 28 May 2021 Results of pooled analysis of two studies (NCT02318706; DS5565-A-J303 & NCT02318719; DS5565-A-J304) assessing mirogabalin safety and efficacy, published in the Clinical Therapeutics.
- 08 Jan 2019 According to a Daiichi Sankyo Company media release, based on the results of REDUCER and NEUCOURSE clinical trials, the company has received marketing approval in Japan for Tarlige Tablets 2.5 mg, 5 mg, 10 mg, 15 mg for the treatment of peripheral neuropathic pain (PNP).
- 01 Aug 2018 Results of pool data from four trials, were published in the Clinical Pharmacology in Drug Development.